CymitQuimica logo
ALK

ALK

ALK inhibitors are compounds that specifically target and inhibit Anaplastic Lymphoma Kinase (ALK), a receptor tyrosine kinase involved in the development and progression of certain cancers, including non-small cell lung cancer and neuroblastoma. By inhibiting ALK, these compounds block signaling pathways that promote tumor cell growth and survival. At CymitQuimica, we offer ALK inhibitors to support your research in oncology, targeted cancer therapies, and signal transduction.

Found 126 products of "ALK"

Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
products per page.
  • CDD-1115
    Targetmol
    + Info

    CDD-1115

    CAS:
    <p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>
    Formula:C32H30N6O3
    Color and Shape:Solid
    Molecular weight:546.619

    Ref: TM-T205172

  • ALKBH5-IN-3
    Targetmol
    + Info

    ALKBH5-IN-3

    CAS:
    ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.
    Formula:C11H7F3N2O3
    Purity:98.32%
    Color and Shape:Solid
    Molecular weight:272.18

    Ref: TM-T201322

  • W23-1006
    Targetmol
    + Info

    W23-1006

    CAS:
    W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).
    Formula:C17H12BrN3O5
    Color and Shape:Solid
    Molecular weight:418.198

    Ref: TM-T205034

  • DA-0157
    Targetmol
    + Info

    DA-0157

    CAS:
    <p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>
    Formula:C31H43BrN7O2P
    Color and Shape:Solid
    Molecular weight:656.597

    Ref: TM-T205118

  • AZ12601011
    Targetmol
    + Info

    AZ12601011

    CAS:
    AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.
    Formula:C19H15N5
    Purity:98.81%
    Color and Shape:Solid
    Molecular weight:313.36

    Ref: TM-T10426

  • Zotizalkib
    Targetmol
    + Info

    Zotizalkib

    CAS:
    TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.
    Formula:C21H20F3N5O3
    Purity:98.7%
    Color and Shape:Solid
    Molecular weight:447.41

    Ref: TM-T9414